Atlas Trials

Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Clinical trial NCT05625737 · UNKNOWN

Trial details

NCT number
NCT05625737
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Stomach Neoplasms
Start date
2022-09-08
Primary completion
2024-12-01
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.